April 5, 2022
Athira Files Definitive Proxy Statement and Mails Letter to Shareholders
April 4, 2022
Athira Pharma Doses First Subject in Phase 1 Clinical Trial of HGF/MET Positive Modulator, ATH-1020, an Orally Available Small Molecule for Neuropsychiatric Conditions
March 30, 2022
Athira Pharma Highlights Strong Execution of Strategy and Positioning for the Future
March 24, 2022
Athira Pharma Reports Full Year 2021 Financial Results and Provides Clinical Update
March 21, 2022
Athira Pharma Announces Appointment of Dr. Michael A. Panzara to its Board of Directors
March 21, 2022
Athira Pharma to Participate in Two Upcoming Investor Conferences
March 20, 2022
Athira Pharma Presents Study Overview and Baseline Data from ACT-AD Phase 2 Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease at the 2022 AD/PD™ Congress
March 17, 2022
Athira Pharma to Host Fourth Quarter and Full Year 2021 Financial Results and Business Update Conference Call on March 24, 2022
March 14, 2022
Athira Pharma to Present Overview and Update from ACT-AD Phase 2 Trial of Fosgonimeton (ATH-1017) in Mild-to-Moderate Alzheimer’s Disease at AD/PD™ 2022 Congress
March 2, 2022
Athira Pharma Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting
Displaying 31 - 40 of 93